Researchers have devised a kit that uses a fluoride-aluminum complex to ease the production of 18F-alfatide, an agent that can zero in on active tumors in squamous or adenomatous lung carcinoma. The method presented a yield of 42.1%, compared with 5% to 25% for the standard method, according to the study published in The Journal of Nuclear Medicine. The agent is being considered as an alternative to 18F-FPPRGD2, which was recently approved. "Because of the simplicity of the method, an advantage is that additional studies can be easily performed in a single day," researchers said.

Related Summaries